Aeropay | $20,000,000 | (May 17, 2024)
Bedrock Materials | $9,000,000 | (May 17, 2024)
OTPLESS | $3,500,000 | (May 17, 2024)
TILT Biotherapeutics Ltd
Finland
- Helsinki
- 08/02/2023
- Unknown
- $23,611,000
TILT Biotherapeutics Ltd is a clinical stage company working in oncology towards enabling T-cell therapies and immune checkpoint inhibitors with oncolytic viruses.
Embodiments of the technology will be used to enhance tumor infiltrating lymphocytes (TILs), chimeric antigen receptor T cells (CAR T) and immune checkpoint inhibiting antibody therapies.
TILT was founded by Pr. Akseli Hemminki, who has published hundreds of papers in the field and treated almost 300 patients with 10 different oncolytic viruses. In 2013, Pr. Hemminki started his second company, TILT Biotherapeutics Ltd, with a technology based on his past findings in the lab, but more importantly in the clinic. The research conducted by TILT alone or in collaboration with some of world’s leading research groups with synergic technologies has generated very excellent results. The lead candidate is a clinical stage TNFα/IL2 armed oncolytic adenovirus (TILT-123 or Ad5/3-E2F-delta24-hTNFα-IRES-hIL2).
Multiple Phase I clinical trials are ongoing.
For contact: BD (at) tiltbio.com
- Industry Biotechnology Research
- Website https://tiltbio.com/
- LinkedIn https://www.linkedin.com/company/tilt-biotherapeutics-ltd/
ekko | $2,500,000 | (May 17, 2024)
Watershed Health | $13,600,000 | (May 17, 2024)
HEPHAISTOS-Pharma | $11,189,199 | (May 17, 2024)
Keyper | $4,000,000 | (May 17, 2024)
c/side | $1,700,000 | (May 17, 2024)
SINE Digital | $2,500,000 | (May 17, 2024)
Angel AI | $4,750,000 | (May 17, 2024)
InstaAstro | $2,300,000 | (May 17, 2024)
Fay | $25,000,000 | (May 16, 2024)